Our focus is mature branded medicines globally. We want to be the preferred purchaser for large cap or speciality pharma businesses choosing to divest. We want to continue the high-quality manufacturing and management of the medicines. We want to breathe new life into the medicines, investing in them to make them stable and sustainable over the long-term.
We want to deliver medicines that our patients, healthcare systems and regulators value. We want to grow our business such that is balanced from both a portfolio and market perspective. We want to maintain a simple, lean operating model, working with partners wherever we can.
First and foremost, our responsibility is to our patients. We commit to adhere to the highest standards of medical practice and to deliver high-quality medicines. We aim to be a responsible business that acts fairly and honestly at all times. We endeavour to manage our supply chain responsibly. We want to give equal opportunities to our employees, to welcome different viewpoints and perspectives, to create a workplace free from harassment and bullying.
Our vendors have different requirements at different stages of the transaction. We understand these requirements and believe we are uniquely positioned to meet them. We want to be the preferred purchaser for large cap or speciality pharma businesses choosing to divest.
A straightforward counterparty capable of rapid execution.
An efficient and experienced transition counterparty.
A trusted and diligent manager for the brand.
We partner with distribution partners to offer as wide a market coverage as possible. Our network now covers over 130 territories. We have offices in Basildon, Copenhagen, New York, Baroda and Sydney.